Treating Cisplatin-Ineligible Metastatic Urothelial Carcinoma: Sarmad Sadeghi, MD, PhD

For many patients with metastatic urothelial carcinoma, cisplatin-containing chemotherapy is not an option; alternative treatments are greatly needed. Recently, the phase 2 California Cancer Consortium trial, led by Sarmad Sadeghi, MD, PhD, reported that a combined regimen of gemcitabine (Gemzar®, Eli Lilly) and eribulin (Halaven®, Eisai Inc.) demonstrates efficacy in cisplatin-ineligible patients with metastatic urothelial carcinoma. In this interview with i3 Health, Dr. Sadeghi discusses the i...
Continue reading

Adavosertib (AZD1775) with Gemcitabine and Radiation for Locally Advanced Pancreatic Cancer: An Interview With Kyle C. Cuneo, MD

Pancreatic cancer is one of the most aggressive forms of cancer, and owing to limited treatment options, it has one of the lowest survival rates. While patients are commonly treated with radiation therapy, there is a need to develop alternative treatment options that can improve the efficacy of radiation, reduce tumor progression, and increase survival. In a recent study, Kyle C. Cuneo, MD, and colleagues evaluated the safety and tolerability of adavosertib (AZD1775), an inhibitor of the Wee1 ki...
Continue reading

Congenital Heart Disease Linked to Cancer: Interview With Zacharias Mandalenakis, MD, PhD

One of the most common birth defects, congenital heart disease (CHD) is associated with an increased risk of developing cancer. Zacharias Mandalenakis, MD and colleagues conducted a study to further explore the link between CHD and cancer. In this interview with i3 Health, Dr. Mandalenakis provides insights on this link and strategies for mitigating risk. What led you to research this topic? Zacharias Mandalenakis, MD, PhD: I am an adult cardiologist, and I work at the Adult Congenital Heart Ass...
Continue reading

The Mortality Risk of Androgen Inhibitors for Prostate Cancer and Heart Disease: An Interview With Grace Lu-Yao, PhD, MPH

Abiraterone acetate and enzalutamide are oral androgen signaling inhibitor therapies used in the treatment of patients with advanced prostate cancer. However, because elderly patients with prostate cancer who also have cardiovascular disease are often excluded from clinical trials, little has been known about the effect of these therapies on the clinical outcomes of these patients. In this interview with i3 Health, Grace Lu-Yao, PhD, MPH, discusses the increased mortality and hospitalization ris...
Continue reading

Utilizing Proper Supportive Care in Multiple Myeloma: An Interview With Smith Giri, MD, MHS

​ In the treatment of multiple myeloma, supportive care is essential to mitigating the risks of infection and bone disease. However, a study published recently in Cancer by Smith Giri, MD, MHS, and colleagues found that guideline-recommended supportive care measures are underutilized in older patients with multiple myeloma. In this interview with i3 Health, Dr. Giri discusses supportive care for patients with myeloma, as well as interventions that could increase the use of these measures. Can yo...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.